Erythropoietin Improves Survival in Mice with Cerebral Malaria
Author Information
Author(s): Lothar Wiese, Casper Hempel, Milena Penkowa, Nikolai Kirkby, Jørgen AL Kurtzhals
Primary Institution: Center for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark
Hypothesis
Does recombinant human erythropoietin (rhEpo) increase survival and reduce neuronal apoptosis in a murine model of cerebral malaria?
Conclusion
Recombinant human erythropoietin significantly increases survival and reduces neuronal apoptosis in mice with cerebral malaria.
Supporting Evidence
- Treatment with rhEpo increased survival in mice with cerebral malaria in a dose-dependent manner.
- The highest survival rates were observed when treatment was administered from day 4 to day 7 post-inoculation.
- RhEpo treatment reduced apoptotic cell death of neurons and the expression of pro-inflammatory cytokines in the brain.
Takeaway
This study found that a medicine called erythropoietin can help mice survive a serious brain infection caused by malaria.
Methodology
Female C57BL/6j mice infected with Plasmodium berghei ANKA were treated with varying doses of rhEpo, and survival rates and brain pathology were assessed.
Limitations
The study used a murine model, which may not fully replicate human cerebral malaria.
Participant Demographics
Female C57BL/6j mice, aged 4-6 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website